Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trial

Mechanisms accounting for sex differences in the incidence of adverse events caused by fluoropyrimidine treatments, and histologic differences in efficacy are insufficiently understood. We determined differences between the sexes in terms of the safety of S-1 plus oxaliplatin (SOX)/bevacizumab-versu...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Glob Health Med
Κύριοι συγγραφείς: Yamada, Yasuhide, Muro, Kei, Takahashi, Keiichi, Baba, Hideo, Komatsu, Yoshito, Satoh, Taroh, Goto, Masahiro, Mishima, Hideyuki, Watanabe, Masahiko, Sakata, Yuh, Morita, Satoshi, Shimada, Yasuhiro, Takenaka, Naruhito, Hirooka, Tadashi, Sugihara, Kenichi
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: National Center for Global Health and Medicine 2020
Θέματα:
Original Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7731258/
https://ncbi.nlm.nih.gov/pubmed/33330814
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.35772/ghm.2020.01050
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια